http://www.finanzen.at/nachrichten/aktien/Further-Study-of-Combination-of-Eisais-Lenvatinib-and-Mercks-Pembrolizumab-in-Previously-Treated-Patients-with-Metastatic-Endometrial-Cancer-Supported-by-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial-1002065395
http://www.finanzen.ch/nachrichten/aktien/Further-Study-of-Combination-of-Eisais-Lenvatinib-and-Mercks-Pembrolizumab-in-Previously-Treated-Patients-with-Metastatic-Endometrial-Cancer-Supported-by-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial-1002065395
http://www.military-technologies.net/2017/06/03/further-study-of-combination-of-eisais-lenvatinib-and-mercks-pembrolizumab-in-previously-treated-patients-with-metastatic-endometrial-cancer-supported-by-interim-analysis-of-ongoing-phase-1b2-tri/
http://www.military-technologies.net/2017/06/03/combination-of-incytes-epacadostat-plus-mercks-keytruda-pembrolizumab-demonstrates-activity-in-clinical-trial-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc-2/
http://www.businesswire.com/news/home/20170603005028/en/Combination-Incyte%E2%80%99s-Epacadostat-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Demonstrates/?feedref=JjAwJuNHiystnCoBq_hl-YorNIXXeJUidDamMzBr2lUAKMtEGtRj-e8KfM-o9q9qrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3miEx88JtThI8BEp2XznrHLRzAC4_rGwOLNoA4bcgbFNw==
http://www.military-technologies.net/2017/06/03/combination-of-incytes-epacadostat-plus-mercks-keytruda-pembrolizumab-demonstrates-activity-in-clinical-trial-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc/
http://www.military-technologies.net/2017/06/03/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless/
http://www.military-technologies.net/2017/06/03/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to/
https://www.dailypolitical.com/2017/06/03/louisiana-state-employees-retirement-system-has-10-72-million-position-in-merck-co-inc-mrk.html
https://www.dailypolitical.com/2017/06/02/addison-capital-co-acquires-shares-of-3425-merck-co-inc-mrk.html
https://www.dailypolitical.com/2017/06/02/howard-capital-management-acquires-930-shares-of-merck-co-inc-mrk.html
http://www.xconomy.com/national/2017/06/03/precision-steps-can-loxo-drug-help-broaden-use-of-cancer-dna-tests/
http://www.military-technologies.net/2017/06/03/combination-of-epacadostat-plus-keytruda-pembrolizumab-demonstrates-activity-in-clinical-trial-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc/
http://www.military-technologies.net/2017/06/02/global-nasal-drug-delivery-technology-market-segmant-spraysdrops-liquids-powders-gels/
http://www.marketwatch.com/story/merck-reports-positive-results-for-late-stage-trial-comparing-its-keytruda-against-bristol-myers-yervoy-2017-06-02
http://www.marketwatch.com/story/merck-reports-positive-results-for-late-stage-trial-comparing-its-keytruda-against-bristol-myers-yervoy-2017-06-02
http://www.prnewswire.com/news-releases/personal-genome-diagnostics-highlights-its-patent-pending-microsatellite-instability-testing-technology-as-fda-approves-keytruda-for-msi-tumors-300467763.html
http://www.marketwatch.com/story/personal-genome-diagnostics-highlights-its-patent-pending-microsatellite-instability-testing-technology-as-fda-approves-keytruda-for-msi-tumors-2017-06-02
http://www.marketwired.com/press-release/evolving-utilization-specific-biomarker-roles-within-trial-design-new-webinar-hosted-2219900.htm
http://www.thejournal.ie/week-in-numbers-152-3416161-Jun2017/
http://timesofindia.indiatimes.com/business/international-business/loxos-targeted-drug-helps-variety-of-advanced-cancers-in-small-study/articleshow/58975935.cms
http://www.channelnewsasia.com/news/health/loxo-s-targeted-drug-helps-variety-of-advanced-cancers-in-small-study-8909766
http://www.dailymail.co.uk/~/article-4568706/index.html
http://www.military-technologies.net/2017/06/03/dynavax-presents-updated-data-for-sd-101-in-combination-with-keytrudar-pembrolizumab-highlighting-an-orr-in-7-out-of-7-patients-naive-to-an-anti-pd-1-or-anti-pd-l1-therapy-3/
http://www.military-technologies.net/2017/06/03/swine-healthcare-market-2017-zoetis-merck-virbac-vetoquinol-merial-sanofi-elanco-eli-lilly/
http://www.military-technologies.net/2017/06/02/dynavax-presents-updated-data-for-sd-101-in-combination-with-keytrudar-pembrolizumab-highlighting-an-orr-in-7-out-of-7-patients-naive-to-an-anti-pd-1-or-anti-pd-l1-therapy-2/
http://www.military-technologies.net/2017/06/02/dynavax-presents-updated-data-for-sd-101-in-combination-with-keytrudar-pembrolizumab-highlighting-an-orr-in-7-out-of-7-patients-naive-to-an-anti-pd-1-or-anti-pd-l1-therapy/
http://247wallst.com/healthcare-business/2017/06/02/15-companies-bracing-for-big-asco-reactions/
http://www.marketwatch.com/story/dynavax-presents-updated-data-for-sd-101-in-combination-with-keytrudar-pembrolizumab-highlighting-an-orr-in-7-out-of-7-patients-naive-to-an-anti-pd-1-or-anti-pd-l1-therapy-2017-06-02
https://www.bloomberg.com/news/articles/2017-06-02/immune-oncology-drug-trials-are-getting-crowded
http://www.marketwired.com/press-release/dynavax-presents-updated-data-sd-101-combination-with-keytrudar-pembrolizumab-highlighting-nasdaq-dvax-2219983.htm
http://www.military-technologies.net/2017/06/02/animal-antimicrobials-market-with-geographic-segmentation-statistical-forecast-and-competitive-landscape-research-upto-2021/
http://www.military-technologies.net/2017/06/02/neogenomics-announces-expansion-of-immuno-oncology-profiling-tests-2/
http://www.military-technologies.net/2017/06/02/short-bowel-syndrome-drugs-2017-global-market-sizestatus-and-forecast-to-2022/
http://www.xconomy.com/national/2017/06/02/bio-roundup-asco-combo-frenzy-maines-free-dna-tests-sema4-more/
http://www.military-technologies.net/2017/06/02/adoptive-cell-therapy-for-cancer-treatment-market-size-trends-and-forecast-2022-business-opportunities-future-investments/
http://www.military-technologies.net/2017/06/02/adoptive-cell-therapy-for-cancer-treatment-industry-production-sales-revenue-and-opportunity-2017-to-2022/
http://www.marketwatch.com/story/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma-2017-06-02
http://www.marketwatch.com/story/neogenomics-announces-expansion-of-immuno-oncology-profiling-tests-2017-06-02
http://www.marketwired.com/press-release/neogenomics-announces-expansion-of-immuno-oncology-profiling-tests-nasdaq-neo-2219903.htm
http://www.military-technologies.net/2017/06/02/global-anti-aging-products-and-therapies-market-is-anticipated-to-surpass-237-8-billion-by-2022-market-research-report-2017/
http://www.military-technologies.net/2017/06/02/global-active-pharmaceutical-ingredients-market-to-surpass-198-8-billion-by-2022-orbis-research/
http://www.emailwire.com/release/392085-North-American-Sleep-aids-Market-is-estimated-to-be-USD-309-Billion-in-the-year-2016-.html
http://www.dailymail.co.uk/~/article-4565018/index.html
http://www.xconomy.com/boston/2017/06/02/mersana-plans-ipo-to-finance-clinical-trials-for-breast-cancer-drug/
https://www.bloomberg.com/news/articles/2017-06-03/cancer-drug-targeting-rare-mutation-works-across-tumor-types
http://www.emailwire.com/release/392999-Human-Microbiome-Market-by-Disease-Data-Validation-Analysis-and-Forecast-2022.html
http://www.military-technologies.net/2017/06/03/veterinary-healthcare-market-global-industry-outlook-analysis-report-2015-2022/
http://www.military-technologies.net/2017/06/03/veterinary-vaccines-market-research-report-market-trends-and-key-developments/
http://www.military-technologies.net/2017/06/02/nanomedicine-market-global-industry-outlook-research-report-2016-2023-by-decisiondatabases/
http://www.military-technologies.net/2017/06/02/asia-pacific-animal-pharmaceutical-market-2017-industry-trends-sales-supply-demand-analysis-forecast-2021/
http://chestertownspy.org/2017/06/02/61990-2/
http://www.emailwire.com/release/392601-Worldwide-Monoclonal-Antibodies-Market-2016-Trend-Analysis-and-Forecast.html
http://www.military-technologies.net/2017/06/02/hepatitis-drugs-market-analysis-2022-latest-trends-top-manufactures-and-business-opportunities/
http://www.pr-inside.com/pulmonary-drug-delivery-devices-market-segment-for-r4601984.htm
https://www.prlog.org/12643813-weight-loss-and-obesity-management-market-report-2017.html
http://www.military-technologies.net/2017/06/02/global-antibacterial-drugs-market-research-growth-opportunities-by-regions-types-applications-trend-forecast-to-2022/
http://www.military-technologies.net/2017/06/02/vaccines-market-based-on-technology-and-indication-captures-the-global-market-very-fast-amr/
http://www.military-technologies.net/2017/06/02/h1-2017-type-2-diabetes-industry-pipeline-review-size-share-trend-and-analysis-research-study/
https://www.siliconrepublic.com/video/biopharma-ambition-2016-panel
http://www.pr-inside.com/geriatric-medicines-market-is-expected-to-reach-us-r4601981.htm
http://www.military-technologies.net/2017/06/02/2017-ankylosing-spondylitis-bekhterevs-disease-h1-market-pipeline-review-size-share-analysis-report/
